Noninvasive determination of heart function by mass spectrometer in Doxorubicin treated patients: Comparison with echocardiographic findings

F. Villani, P. De Maria, R. Meazza

Research output: Contribution to journalArticle

Abstract

Purpose: The aim of our study was to evaluate cardiac index (CI), stroke volume index (SVI) and their fluctuations during Doxorubicin therapy in patients with metastatic breast cancer. Methods: The haemodynamic parameters obtained with a novel non-invasive technique based on a spectrometer determination of the rebreathing of a gas mixture composed of oxigen, SF6 and acetilene, were then compared with 2D echocardiographic values. 31 adult patients (mean age 48.4 ± 9.5 years) submitted to chemotherapy with Doxorubicin were enrolled in the study. The mean cumulative dose od Doxorubicin was 329 ± 60 mg/mq with a range of 240-480 mg/mq. The heart function of these 31 patients was evaluated in basal condition and 1 month after the completion of their anticancer treatment. Results: CI SVI LVEDD LVESD EF L/min mq mL/mq cm cm % basal 3.36±0.5 35.1±4.5 4.6±0.1 3.1±0.2 60.5±4.9 treatment 2.82±0.5 29.1±6.4 4.8±0.2 2.9±0.3 57.6±4.8 p 0.0001 0.001 0.01 NS 0.002 Conclusions: These data demonstrate the usefulness of the novel non-invasive technique, the acetilene rebreathing test, for cardiac monitoring of Doxorubicin treated patients and confirm that the well known cardiac function deterioration can be detectable also at cumulative dose lower than 550 mg/mq, usually considered the limiting safe border.

Original languageEnglish
JournalChest
Volume110
Issue number4 SUPPL.
Publication statusPublished - Oct 1996

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Fingerprint Dive into the research topics of 'Noninvasive determination of heart function by mass spectrometer in Doxorubicin treated patients: Comparison with echocardiographic findings'. Together they form a unique fingerprint.

  • Cite this